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Key questions
What is already known?
 ► Cardiac resynchronisation therapy (CRT) continues 
to have a 30% non-response rate.
 ► Maladaptive processes of neurohumoral activation 
and cardiac extracellular matrix remodelling are 
central to development and progression of heart 
failure (HF).
What does this study add?
 ► First prospective pilot study to evaluate cardiac 
fibrosis biomarkers and specific dysregulated mi-
cro-RNA in patients with HF undergoing CRT.
 ► Selected baseline biomarkers and clinical variables 
did not demonstrate any ability to predict functional 
response, although C-terminal telopeptides (and left 
bundle branch block) trended towards significance.
 ► Levels of N-terminal pro-peptides of collagen I and 
miR-122 following CRT were shown to vary signifi-
cantly between responders and non-responders.
 ► Expression over time in both groups was shown to 
alter for matrixmetalloproteinase (MMP)-2, MMP-9 
and high-sensitivity Troponin-T.
How might this impact clinic practice?
 ► Knowledge of circulating vascular biomarker in pa-
tients with HF undergoing CRT may help in better 
understanding the underlying mechanisms of CRT.
 ► Use of vascular biomarkers to predict CRT response 
could have an impact on the significant non-re-
sponse rate seen in CRT patients. This has clinical 
and financial implications for healthcare systems 
worldwide.
AbstrAct
Aims Cardiac resynchronisation therapy (CRT) is effective 
treatment for selected patients with heart failure (HF) 
but has ~30% non-response rate. We evaluated whether 
specific biomarkers can predict outcome.
Methods A prospective single-centre pilot study of 
consecutive unselected patients undergoing CRT for HF 
between November 2013 and December 2015 evaluating 
cardiac extracellular matrix biomarkers and micro-
ribonucleic acid (miRNA) expression before and after 
CRT assessing ability to predict functional response and 
survival. Each underwent three assessments (pre-implant, 
6  weeks and 6  months postimplant) including: New 
York Heart Association (NYHA) class, echocardiography, 
electrocardiography, 6  min walk test (6MWT), Minnesota 
Living with Heart Failure Questionnaire (MLHFQ) and 
N-terminal pro-brain natriuretic peptide (NT-pro-
BNP). Plasma markers of cardiac fibrosis assessed 
were: N-terminal pro-peptides of collagen I and III, 
collagen I C-terminal telopeptides (CTx) and matrix 
metalloproteinases (MMP-2 and MMP-9) as well as a 
panel of miRNAs (miRNA-21, miRNA-30d, miRNA-122, 
miRNA-133a, miRNA-210 and miRNA-486).
Results A total of 52 patients were recruited; 
mean age (±SD) was 72.4±9.4 years; male=43 
(82.7%), ischaemic aetiology=30 (57.7%), mean QRS 
duration=166.4±23.5  ms, left bundle branch block 
(LBBB) morphology = 39 (75.0%), mean NYHA=2.7±0.6, 
6MWT=238.8±130.6  m, MLHFQ=46.4±21.3  and left 
ventricular ejection fraction (LVEF)=24.3%±8.0%. Mean 
follow-up=1.7±0.3  and 5.8±0.7 months. There were 27 
(55.1%) functional responders (3 no definable 6-month 
response; 2 missed assessments and 1 long-term lead 
displacement). No marker predicted response, however, 
CTx and LBBB trended most towards predicting functional 
response.
Conclusion No specific biomarkers reached significance 
for predicting functional response to CRT. CTx showed a 
trend towards predicting response and warrants further 
study.
Trial registration number NCT02541773.
InTRoduCTIon
Heart failure with reduced ejection fraction 
(HFrEF) is characterised by adverse cardiac 
remodelling with progressive reduction in 
left ventricular (LV) ejection fraction and 
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poor cardiovascular outcomes.1 Cardiac resynchronisa-
tion therapy (CRT) has revolutionised management by 
reducing mortality and morbidity1 with reverse cardiac 
remodelling induced by CRT. Unfortunately, CRT non-re-
sponse occurs in 20%–40% of patients despite meeting 
implant criteria.1 Maladaptive processes of neurohumoral 
activation, cardiac extracellular matrix (ECM) remodel-
ling, proinflammatory changes and myocardial wall stress 
are central to development and progression of HFrEF.2 
Altered ECM turnover in HFrEF is directly associated 
with adverse cardiac remodelling3 and biomarkers of 
collagen synthesis (N-terminal pro-peptides of collagen 
I (PINP), carboxy-terminal pro peptide of procollagen 
type 1 (PICP) and N-terminal pro-peptides of collagen 
III (PIIINP)) and degradation (cross linked carboxy-telo-
peptide of type 1 collagen (ICTP) or carboxy-terminal 
telopeptide of collagen 1 (CITP)) have been shown to be 
associated with poor heart failure (HF) outcomes. As key 
regulators of ECM turnover, matrix metalloproteinases 
(MMP-2 and MMP-9) have been implicated as biomarkers 
of HF diagnosis and prognosis.4 Growth Differentiation 
Factor-15 (GDF-15) is a member of the transforming 
growth factor-β cytokine superfamily involved in regu-
lation of cell survival, proliferation and differentiation 
that is associated with poor HF outcomes and has been 
suggested as a predictor of CRT response.5
Micro-ribonucleic acids (miRNAs) are short (20–22 
nucleotides) endogenous non-coding ribonucleic acids 
and are key regulators of gene expression, including 
within the cardiovascular system;6 miRNAs are readily 
measured in blood and several circulating miRNAs have 
been shown to be dysregulated in cardiovascular disease, 
suggesting potential use as biomarkers.6 7Specifically, 
miR-21,8 miR-30d,9 miR-1228, miR-133a,6 and miR-2106 
are dysregulated in adverse cardiac remodelling and 
HFrEF.
Markers of collagen turnover have previously been 
studied to establish their value as predictors of CRT 
response, but outcomes have thus far been inconsistent;4 
miRNAs are novel biomarkers with variation reported 
in HFrEF,6 but limited information is available on their 
ability to predict CRT response.7 9 Our aim was to char-
acterise biomarkers of ECM remodelling and established 
dysregulated miRNAs before and after CRT to assess 
whether they predict CRT response and survival.
MeTHods
The COVERT-HF study was a prospective study of unse-
lected patients with HFrEF undergoing CRT at a single 
tertiary centre between November 2013 and June 2015. 
The trial was registered at  clinicaltrials. gov (reference 
NCT02541773). Participants were eligible if they met 
National Institute of Clinical Excellence (NICE)10 criteria 
for CRT. Patients with atrial fibrillation or those requiring 
CRT-upgrade were included to reflect real-world prac-
tice.10 Patients were excluded if they had a recent acute 
coronary syndrome or acute HF decompensation (<6 
weeks), end-stage renal disease (on renal replacement 
therapy), significant cognitive impairment or terminal 
illness (expected survival<1 year). Postimplantation 
exclusions were applied in case of procedure failure or 
complications resulting in unsuccessful CRT pacing (eg, 
lead displacement/phrenic nerve pacing). Each partici-
pant underwent a preimplantation visit and two follow-ups 
at 6 weeks and 6 months postimplant. Participants had 
NewYork Heart Association (NYHA) class assessment, 
6 min walk test (6MWT), Minnesota Living with Heart-
Failure Questionnaire (MLHFQ), transthoracic echocar-
diography, resting 12-lead electrocardiography (ECG) 
and blood sampling at all attendances. All provided 
written informed consent. The study was conducted in 
accordance with the Declaration of Helsinki.
study outcomes
The primary outcome measure was functional response 
status. Functional responders were defined as those 
who survived, did not undergo heart transplantation 
and achieved two of three response criteria (↓>1 NYHA, 
↑>10% 6MWT distance, ↓MLHFQ score>5) at 6 months 
follow-up. Secondary outcomes were: echocardiographic 
response (defined as >15% reduction in LV end-systolic 
volume at 6 months) and major adverse cardiovascular 
events (MACE) defined as a composite of all-cause 
mortality and first HF hospitalisation.
device implantation
All elective implantations were performed as day-cases as 
previously reported.11
Transthoracic echocardiography
All underwent transthoracic echocardiography (Vivid 
7, GE Healthcare, Horten, Norway) for LV volumetric 
assessment performed on the same machine by the 
same nationally accredited operator for each study 
visit. All measurements were analysed offline (EchoPac, 
GE Healthcare, Horten, Norway). LV ejection fraction 
was estimated using the biplane modified Simpsons 
method.12 A blinded inter-rater study was conducted on 
a randomly selected 20% of study participants. The inter-
rater study for available comparative measures demon-
strated strong correlation between rater measurements 
(r2=0.90, p<0.01). Paired measurements were not signifi-
cantly different between both raters when compared with 
paired t-test (p=0.90). Bland-Altman limits of agreement 
were calculated to be 20.7%.
Blood sampling and laboratory analysis
Peripheral venous sampling of blood was performed 
following 2 hours of fasting and 1 hour of rest, using 
EDTA as anticoagulant. Serum and plasma were prepared 
by single centrifugation at 3500 RPM for 10 min, followed 
by storage at −80°C until analysis. Preimplant peripheral 
samples were taken the morning of implant. Coronary 
sinus sampling was performed in half the cohort (n=26) 
during CRT implantation on cannulation of the coronary 
sinus. Clinical laboratory measurements were performed 
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according to standard hospital procedure. Electrochem-
iluminescence Immunoassay analysis (Cobas, Roche 
Diagnostics, Basel, Switzerland) for N-terminal pro-brain 
natriuretic peptide (NT-pro-BNP) and high-sensitivity 
Troponin-T (hs-TnT) were performed. Plasma levels 
PINP and C-terminal telopeptides (CTx) were deter-
mined using an ECLIA Cobas 8000 modular analyser 
(Roche Diagnostics, Basel, Switzerland). The immuno-
assays interassay and intra-assay precision for PINP was 
<3.0%, and for CTx was <2.5%. The assays manufacturer 
calculated measures and were locally validated according 
to the validated international Clinical and Laboratory 
Standards Institute EP05-A3 protocol. Sandwich ELISAs 
were used to determine plasma levels of GDF-15, MMP-2 
and MMP-9 (R&D Systems, Minneapolis, Minnesota, 
USA) and PIIINP (Cusabio, Wuhan, Hubei, China) 
according to manufacturers’ protocol. The interassay 
and intra-assay coefficient of variability was calculated for 
each assay: GDF-15 (7.7% and <4.8%); MMP-2 (4.5% and 
<5.6%); MMP-9 (10.3% and <12.9%); PIIINP (5.1% and 
<7.2%).
MiRNA profiling was specifically undertaken for 
miR-218, miR-30d,9 miR-1228, miR-133a,6 and miR-2106 
due to their previously reported dysregulation in HFrEF. 
MiR-486 was also profiled and used as a marker for 
sample quality for haemolysis as it is highly enriched in 
erythrocytes.13 Profiling was performed using previously 
described methods.14 Total RNA, including small RNA, 
was extracted from 100 µl of plasma using the miRNeasy 
Mini kit (Qiagen, Hilden, Germany). An exogenous 
miRNA (cel-miR-39-3 p) was spiked in to the plasma at 
the start of the extraction procedure to serve as a normal-
isation control. MiRNAs were reverse-transcribed using 
the TaqMan MicroRNA Reverse Transcription Kit and 
RT Megaplex Primer pools (Human Pools A V.2.1 and 
B V.2.0, Applied Biosystems, Darmstadt, Germany) and 
further amplified using TaqMan PreAmp Master Mix and 
Megaplex PreAmp Primers (Primers A V.2.1 and B V.2.0, 
Life Technologies, Massachusetts, USA). TaqMan miRNA 
assays (Applied Biosystems) and TaqMan Universal PCR 
Master Mix, AmpErase UNG were used for quantitative 
real-time PCR (qPCR) of specified miRNAs on a ViiA7 
Real-Time PCR System (Life Technologies) at 50°C for 
2 min, 95°C for 10 min, followed by 40 cycles of 95°C 
for 15 s and 60°C for 1 min. Relative quantification 
was performed using the 2-ΔΔCt method.15 Haemolytic 
samples were excluded from the analysis. Every patient 
had three sets of samples taken at each time point (unless 
they died at follow-up) and all samples were available for 
analysis.
statistical analysis
Statistical analysis was performed using Statistical Package 
for Social Sciences (SPSS), V.22.0 (IBM, Chicago, Illinois, 
USA). Categorical variables were reported as frequency 
and percentages. Comparison analyses for categor-
ical data were performed using the χ² or Fisher’s exact 
tests, dependent on appropriateness. Continuous data 
underwent histogram plots for assessment of normality. 
Normally distributed data were reported as mean±SD 
and comparative analysis performed using independent 
t-tests. Non-normally distributed data were reported 
as median (full range) and compared using Mann-
Whitney U test. Paired continuous data were analysed 
using paired t-test or Wilcoxon Signal Rank test, as 
appropriate. Non-normally distributed ECM biomarkers, 
NT-pro-BNP, GDF-15 and hs-TnT data were presented 
unadjusted; however, they were transformed logarithmi-
cally for analysis. Fold change was calculated using the 
mean (responder/non-responders) cohort value when 
comparing two independent datasets. The fold change 
for paired data sets was also calculated using matched 
means (coronary sinus/peripheral). Variation in contin-
uous variables over three time periods was analysed using 
either one-way analysis of variance (ANOVA) or Friedman 
test, respectively. Mixed between-within subjects ANOVA 
was used to compare variation in continuous data in func-
tional responders and non-responders over 6 months. 
Bivariate correlation analysis with either Pearson (para-
metric) or Spearman rank (non-parametric) estimators 
was performed between two continuous variables to 
explore relationships. Univariate logistic regression anal-
ysis was performed for functional response for prede-
fined vascular biomarkers and established clinical vari-
ables. Those with p<0.2 were pooled as covariants for 
multiple logistic regression. A high alpha was set on the 
basis of the clinical response definition. A stepwise entry 
method was applied with forward selection and back-
ward elimination. The accuracy of the model was verified 
with a Hosmer-Lemeshow goodness-of-fit test. P<0.05 was 
considered statistically significant. Given the limited data 
in this field, we were unable to perform a power calcula-
tion at the start of our study. We, therefore, performed 
this single-centre pilot study to be able to more accurately 
predict power for the most prominent biomarkers found 
enabling a larger multicentre trial to be done. Following 
completion of our study, we were able to perform a power 
calculation based on the two most important predictors 
noted (PINP and CTx). In order to demonstrate a signifi-
cant difference between baseline concentrations in PINP 
and CTx as predictors of response (assuming a non-re-
sponse rate 40%), a sample size of 430 was calculated and 
assumed an 80% power with significance level of p=0.05.
ResulTs
A total of 58 patients were consented and 52 included in 
the study (figure 1). Follow-up visits occurred at 1.7±0.3 
and 5.7±0.7 months, respectively. There were 27 (59.1%) 
responders and 22 (44.9%) non-responders after 6 
months follow-up.
Baseline clinical characteristics
Baseline characteristics and functional response 
are shown in table 1. There were 43 (82.7%) males 
with mean age of 72.4±9.4 years with no significant 
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Figure 1 Patient recruitment, flow and outcomes. CRT, cardiac resynchronisation therapy; HF, heart failure.
difference between responders and non-responders; 30 
(57.7%) had ischaemic and 22 (42.3%) non-ischaemic 
aetiology, which did not significantly vary by response 
status. Median (+range) QRS duration was 164.0 ms 
(120.0–240.0) and 39 (75.0%) had baseline LBBB. Both 
QRS duration (168.0 ms vs 159.0 ms, p=0.11) and LBBB 
morphology (85.2% vs 63.6%, p=0.16) did not vary 
significantly between responders and non-responders, 
respectively. There was a trend for wider QRS and pres-
ence of LBBB in responders. The three patients lost 
during follow-up did not change the cohort character-
istics.
Baseline biomarker levels
Table 2 shows baseline ECM biomarkers and miRNA 
for the cohort and by functional response status. 
There was no significant difference in expression of 
ECM biomarkers of collagen synthesis or degradation 
between functional responders and non-responders at 
baseline. Baseline levels of type I collagen degradation 
(CTx) were observed to be more highly expressed in 
responders than non-responders, but did not reach 
statistical significance (0.48 (0.14–1.14) ug/L vs 0.31 
(0.16–0.73) ug/L, p=0.07). The biomarker of myocar-
dial stress, GDF-15, was not demonstrated to have 
significant variation in expression between responders 
and non-responders (1.12 (1.12–10.29) ug/L vs 1.20 
(2.75–5.95) ug/L, p=0.42). MiRNA biomarker expres-
sion profiles did not vary significantly between func-
tional responders and non-responders; however, a trend 
for changes in miR-133a was observed (fold change 
0.65, p=0.08). MiR-486 was found to have no significant 
difference between responder and non-responders at 
baseline (fold-change 1.16, p=0.76).
effects of CRT on cardiac function and biomarker expression
The impact of implanting CRT was examined for func-
tional variables, LV geometry and biomarker expression 
over 6 months. Trends between functional responders 
and non-responders were compared. Online supple-
mentary file 1 demonstrates functional variables, LV 
geometry measurements and biomarker levels at base-
line and changes at follow-up. Figure 2 demonstrates 
the most significant changes in 6MWT, LVEF, PINP and 
MMP-2 over the period of follow-up for changes over 
time and between groups. Quality of life scores and left 
ventricular end systolic volume (LVESV) both improved 
following CRT implantation for responders and non-re-
sponders (p<0.01). MMP-9 had decreased expression in 
both groups over the follow-up period (p=0.01). MiR-122 
(a liver-specific miRNA) was the only miRNA to have 
significantly higher initial expression in non-responders 
compared with responders (p=0.03). MiR-486 expression 
trended towards a significant decrease in expression in 
both responders and non-responders (p=0.05).
Correlation between change in biomarker expression and 
cardiovascular variables following CRT
Correlation analysis was performed for relative change 
during short/long-term follow-up between prespecified 
biomarkers and functional parameters, LV geometry 
measures and NT-pro-BNP. Figure 3 shows the strongest 
associations found. Further significant associations in 
short-term relative changes following CRT implantation 
were noted between LVESV/PIIINP (r=0.39, p=0.04) and 
NT-pro-BNP/miR-133a (r=−0.34, p=0.03). Additional 
associations were observed between relative long-term 
changes in NT-pro-BNP with miR-133a (r=−0.50, p≤<0.01) 
and MMP-9 (r=−0.32, p=0<0.03).
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Table 1 Baseline cohort characteristics
Total cohort, n=52 Responders, n=27 Non-responders, n=22 P values
Demographics
  Age (years, mean±SD) 72.4±9.4 72.0±10.4 73.0±8.5 0.74
  Male (n,%) 43 (82.7%) 23 (85.2%) 17 (77.3%) 0.74
Device
  ICD: primary prevention (n, %) 26 (78.8%) 16 (88.9%) 9 (64.3%) 0.22
  Upgrade (n, %) 14 (26.9%) 5 (18.5%) 9 (40.9%) 0.16
Aetiology
  Ischaemic (n, %) 30 (57.7%) 15 (55.6%) 13 (59.1%) 1.00
  Non-ischaemic (n, %) 22 (42.3%) 12 (44.4%) 9 (40.9%)
Comorbidities
  History of atrial fibrillation (n, %) 28 (53.8%) 14 (51.9%) 12 (54.5%) 1.00
  Diabetes mellitus (n, %) 15 (28.8%) 5 (18.5%) 9 (40.9%) 0.16
  COPD (n, %) 10 (19.2%) 3 (11.1%) 6 (27.3%) 0.28
  CKD (n, %) 23 (44.2%) 11 (40.7%) 12 (54.5%) 0.5
NYHA (n, %) II 20 (38.5%) 11 (40.7%) 8 (36.4%) 0.25
  III 27 (51.9%) 15 (55.6%) 10 (45.5%)
  IV 5 (9.6%) 1 (3.7%) 4 (18.2%)
Routine blood markers
  eGFR (mL/min/1.73 m2, median, range) 61.5 (25.0–130.0) 59 (25.0–130.0) 58.0 (26.0–99.0) 0.36
  Haemoglobin (g/L, mean±SD) 134.4±13.5 136.6±14.1 132.5±12.5 0.28
  NT-pro-BNP (pmol/L, median, range) 248.7 (53.0–4138.0) 207.0 (53.0–4138.0) 255.5 (67.0–547.0) 0.37
  hs-TnT (ng/L, median, range) 26.5 (6.5–233.0) 26.4 (8.5–233.0) 27.6 (6.5–61.8) 0.78
Medications
  ACEi/ARB (n, %) 50 (96.2%) 26 (96.3%) 21 (95.5%) 1.00
  BB (n, %) 44 (84.6%) 22 (81.5%) 21 (95.5%) 0.24
  MRA (n, %) 34 (65.4%) 17 (63.0%) 14 (63.6%) 0.96
  Aspirin (n, %) 24 (46.2%) 13 (48.1%) 9 (40.9%) 0.83
  Clopidogrel (n, %) 6 (11.5%) 3 (11.1%) 3 (13.6%) 1.00
  Prasugrel (n, %) 1 (1.9%) 1 (3.7%) 0 (0.0%) 1.00
ECG
  Atrial Fibrillation (n, %) 19 (36.5%) 9 (33.3%) 8 (36.4%) 0.5
  QRS duration (ms, median, range) 164.0 (120–240) 168.0 (146–240) 159.0 (120–210) 0.11
  LBBB (n,%) 39 (75.0%) 23 (85.2%) 14 (63.6%) 0.16
QoL Score (median, range) 48.5 (8–101) 50 (9–86) 48.5 (8–101) 0.77
6MWT (M, mean±SD) 238.8±130.6 237.6±130.5 239.4±127.4 0.95
Echocardiogram
  LVEDD (mm, mean±SD)* 61.7±10.1 62.9±11.2 60.2±9.0 0.4
  LVESV (mL, median, range)* 111.5 (49–219) 119.3 (49–269) 110.2 (56–169) 0.41
  LVESV_BSA (mL, mean±SD)* 61.3±21.5 65.7±25.8 56.6±16.3 0.26
  LVEF (%, mean±SD)* 24.3±8.0 24.1±7.9 24.4±8.7 0.91
LV lead circumferential position (n, %)
  Anterior 5 (9.6%) 2 (7.4%) 3 (13.6%) 0.64
  Anterolateral 3 (5.8%) 2 (7.4%) 1 (4.5%)
  Lateral 28 (53.8%) 13 (37.0%) 13 (59.1%)
  Posterolateral 16 (30.8%) 10 (37.0%) 5 (22.7%)
Continued
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Total cohort, n=52 Responders, n=27 Non-responders, n=22 P values
LV lead axial position
Basal (n, %)
29 (55.8%) 15 (55.6%) 11 (50.0%) 0.7
  Mid-Cavity (n, %) 23 (44.2%) 12 (44.4%) 11 (50.0%)
~ = proportion of patients with defibrillators only,
*Represents data available.
ACEi, angiotension converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker; BSA, body surface area; CABG, 
coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular 
filtration rate; LBBB, left bundle branch block; LVEDV, LV end diastolic volume; LVEF, left ventricular ejection fraction; LVESD, LV end systolic 
diameter; LVESV, left ventricular end systolic volume; LVIDD, LV end diastolic diameter; MI, myocardial Infarction; MRA, mineral corticoid 
receptor antagonist; PCI, percutaneous coronary intervention; QoL, Qualiy of Life.
Table 1 Continued
Table 2 Baseline biomarker levels for functional responders and non-responders
Total cohort=52 Responders=27 Non-responders=22 P values
PINP (ug/L, median, range) 40.0 (15.0–141.0) 43.0 (22.0–141.0) 38.0 (15.0–113.0) 0.53
CTx (ug/L, median, range) 0.40 (0.14–1.14) 0.48 (0.14–1.14) 0.31 (0.16–0.73) 0.07
PIIINP (ug/L, mean±SD) 1.02±0.39 1.09±0.35 0.94±0.43 0.11
MMP-2(ug/L, median, range) 277.3 (155.3–789.5) 258.8 (157.0–789.5) 323.5 (155.3–543.4) 0.13
MMP-9 (ug/L, median, range) 73.5 (13.6–254.1) 71.8 (13.6–254.1) 80.8 (13.6–254.1 0.47
GDF-15 (ug/L, median, range) 2.66 (1.12–10.29) 2.66 (1.12–10.29) 2.75 (1.20–5.95) 0.42
miR-21 (RQ, median, range) 0.8 (0.3–2.4) 0.77 (0.3–1.9) 0.82 (0.5–2.4) 0.72
miR-30d (RQ, median, range) 0.7 (0.2–2.55) 0.81 (0.2–2.55) 0.68 (0.29–2.27) 0.35
miR-122 (RQ, median, range) 0.50 (0.06–3.60) 0.45 (0.08–3.60) 0.69 (0.06–2.48) 0.27
miR-133a (RQ, median, range) 0.78 (0.01–4.52) 0.34 (0.01–4.52) 1.28 (0.01–3.79) 0.08
miR-210 (RQ, median, range) 0.76 (0.03–5.12) 0.57 (0.17–5.12) 0.79 (0.03–3.61) 0.36
miR-486 (RQ, median, range) 0.76 (0.17–3.14) 0.87 (0.17–3.14) 0.73 (0.21–2.48) 0.76
CTx, C-terminal telopeptides; GDF-15, Growth Differentiation Factor-15; MMP-2, matrixmetalloproteinase-2; PINP, N-terminal pro-peptides 
of collagen I; PIIINP, N-terminal pro-peptides of collagen III; RQ, relative quantity.
Predicting functional response
Prespecified baseline ECM, GDF-15 and miRNA 
biomarkers, alongside established clinical parameters 
underwent logistic regression modelling to build a predic-
tion model for functional response. Figure 4 shows the 
univariate and multivariate model for preimplant param-
eters and their ability to predict functional response. 
There were two variables on multivariate modelling 
which trended towards predicting long-term functional 
response; these were increasing baseline CTx expression 
and presence of LBBB morphology on resting ECG.
echocardiographic response and baseline biomarker 
expression
Echocardiographic response was established in 28 partic-
ipants, due to limitations in the ability to perform paired 
LV volumetric assessments secondary to suboptimal 
image quality and body habitus; there were 12 (42.9%) 
responders and 16 (57.1%) non-responders. Baseline 
comparison of biomarker expression was performed 
between these echocardiographic responders and non-re-
sponders (table 3).
Adverse events
During the 1-year observation period following CRT, 
there were 8 (15.4%) MACEs at a median 2.8 (0.1–11.9) 
months. There were 4 (7.7%) all-cause mortalities at 
median of 3.7 (0.1–9.6) months. There were 6 (11.5%) 
hospital admissions for first HF event after CRT which 
occurred at median of 2.8 (1.3–11.9) months. Baseline 
characteristics for those with/without MACE were not 
significantly different for any parameter or baseline 
biomarker expression. Online supplementary file 1 
compares baseline biomarker expression dependent on 
MACE occurrence in the following year.
Coronary sinus biomarker profile
Coronary sinus and peripheral venous sampling were 
conducted on a subset of the study cohort (n=26) on the 
day of implant (only paired samples compared). Haemo-
lysed samples were excluded from respective analyses. 
Figure 5 shows those biomarkers that demonstrated 
significant variation in their expression. Expression 
was higher in the coronary sinus for hs-TnT (p<0.01), 
miR-30d (fold change 1.29, p=0.05) and −133a (fold 
7McAloon CJ, et al. Open Heart 2018;5:e000899. doi:10.1136/openhrt-2018-000899
Heart failure and cardiomyopathies
Figure 2 Trends in functional variables, LV geometry and biomarker expression following CRT implantation in responders 
and non-responders. Trends represent the mean value of responders or non-responders. Differences over time and between 
response status were tested. 6MWT and LVEF are presented as mean (95% CI). PINP (ug/L) and MMP-2 (ug/L) are presented 
as median (CI 95%). CRT, cardiac resynchronisation therapy; LV, left ventricle; MMP-2, matrixmetalloproteinase-2; 6MWT, 6 min 
walk test; PINP, N-terminal pro-peptides of collagen I.
change 3.36, p<0.01). Notably miR-486 had significantly 
higher expression in the coronary sinus (fold change 1.43, 
p<0.01), which is in keeping with the higher haemolysis 
rate observed in coronary sinus sampling. PINP, PIIINP 
and MMP-2 all had significantly higher expression in 
peripheral samples than coronary sinus (p<0.01), this 
was observed for both responders and non-responders 
(p<0.01); hs-TnT demonstrated significantly higher 
expression in non-responders in coronary sinus than 
peripheral samples (28.8 ng/L (6.5–61.6) vs 38.4 ng/L 
(10.3–60.6], p<0.01). No statistical difference in hs-TnT 
levels for responders was observed between peripheral 
and coronary sinus samples (23.4 ng/L (8.5–68.2) vs 27.5 
ng/L (17.7–64.7), p=0.14).
dIsCussIon
Our pilot study is the first to prospectively evaluate 
cardiac fibrosis biomarkers and dysregulated miRNA in 
patients with HF undergoing CRT to determine their 
potential to predict functional response. It is the first 
study, to our knowledge, to profile specific miRNAs that 
are known to be dysregulated in patients with HFrEF. 
Preimplant, there were no significant differences 
between expressions in the prespecified biomarkers. 
None of the predefined biomarkers demonstrated 
ability to predict functional response; however, CTx 
and LBBB morphology trended towards significance. 
However, levels of PINP and miR-122 following CRT 
implantation were shown to vary significantly between 
responders and non-responders. Expression over 
time in both groups was shown to alter for MMP-2, 
MMP-9 and hs-TnT. Furthermore, specific changes 
in biomarker expression were shown to be associated 
with changes in functional, neurohormonal and LV 
geometry parameters both in short-term and long-term 
follow-up. The study also showed higher expression 
of cardiac fibrosis biomarkers systemically and higher 
expression of miRNAs in the coronary sinus.
Cardiac fibrosis biomarkers are known to be strongly 
associated with poor HF outcomes.2 Alteration in ECM 
turnover is a key feature of cardiac fibrosis and strongly 
associated with development and progression of HFrEF.3 
Over the last decade, specific ECM biomarkers have 
been associated with poor HF outcomes2 and to predict 
response to CRT.4 Alteration in collagen synthesis and 
deposition, demonstrated by PINP/PICP for type I 
and PIIINP for type III, have been observed to predict 
response in several observational studies for functional 
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Figure 3 Bivariate correlation analysis of short-term and long-term changes following CRT between biomarkers versus 
functional and echocardiographic variables. Relative change applied to short-term (6 weeks) and long-term (6 months) reviews 
compared with the baseline assessments. Relative change was calculated by follow-up-Baseline/Baseline. Parametric or non-
parametric bivariate correlation analysis performed dependent of continuous data distribution. All prespecified biomarkers 
compared with were 6MWT, QoL score, NT-pro-BNP, LVESV and LVEF. CRT, cardiac resynchronisation therapy; LV, left ventricle; 
MMP-2, matrixmetalloproteinase-2; 6MWT, 6 min walk test; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; PINP, 
N-terminal pro-peptides of collagen I; PIIINP, N-terminal pro-peptides of collagen III.
and echocardiographic criteria. The exact behaviour 
and significance of collagen turnover have not been 
consistently replicated,4 principally due to variation 
in response definitions. No biomarkers in our study 
predicted response; CTx trended towards predicting 
response but did not reach significance. No statisti-
cally significant differences in ECM biomarker expres-
sion were demonstrated between echocardiographic 
responders or those with/without MACE. A substudy 
of the CARE-HF trial1 examined ECM biomarkers 
(PINP, PIIINP, ICTP, MMP-1) as potential predictors 
of response (survival and LVEF >35% at 18 months); 
they showed none predicted response, in keeping 
with our observations.16 More recently, The Markers 
and Response to CRT (MARC) study tested multiple 
pre-specified variables including ECM biomarkers 
(PIIINP, ICTP, PICP, MMP-9, TIMP-1) and they also 
showed none predicted CRT response (defined as 
↓>LVESVi at 6 months).17 Our study demonstrated 
that reduction in PIIINP expression at 6 months was 
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Figure 4 Univariate and multivariate regression model of pre-CRT implant variables for prediction of functional response at 6 
months. Forrest plot demonstrated the OR and 95% CI for parameters in univariate analysis. The table demonstrated the final 
step in the multivariate analysis. ECM, GDF-15 and NT-pro-BNP were logarithmically transformed for the prediction model. 
ECM, extracellular matrix; GDF-15, Growth Differentiation Factor-15; NT-pro-BNP, N-terminal pro-brain natriuretic peptide.
Table 3 Comparison of baseline biomarker expression between with and without >15% reduction in LVESV at 6 months 
following CRT
Biomarkers Responders=12 Non-responders=16 P values
PINP (ug/L, median, range) 39.5 (24.0–69.0) 48.0 (26.0–141.0) 0.14
CTx (ug/L , median, range) 0.47 (0.14–1.14) 0.48 (0.18–0.90) 0.94
PIIINP (ug/L, mean±SD) 1.05±0.43 1.08±0.46 0.87
MMP-2(ug/L , median, range) 247.5 (155.3–671.5) 342.5 (194.0–789.5) 0.05
MMP-9 (ug/L , median, range) 77.5 (24.7–182.3) 70.4 (13.6–204.2) 0.51
GDF-15 (ug/L , median, range) 1.96 (1.12–4.28) 2.46 (1.20–10.29) 0.24
miR-21 (RQ, median, range) 0.86 (0.50–1.40) 0.77 (0.60–2.30) 0.63
miR-30d (RQ, median, range) 0.64 (0.34–1.68) 0.91 (0.35–1.86) 0.39
miR-122 (RQ, median, range) 0.46 (0.06–3.28) 0.84 (0.09–3.60) 0.16
miR-133a (RQ, median, range) 0.53 (0.01–3.79) 0.80 (0.08–2.26) 0.66
miR-210 (RQ, median, range) 0.42 (0.17–2.05) 0.85 (0.06–5.12) 0.15
miR-486 (RQ, median, range) 0.81 (0.17–1.93) 0.72 (0.21–2.48) 0.98
CRT, cardiac resynchronisation therapy; CTx, C-terminal telopeptides; GDF-15, Growth Differentiation Factor-15; MMP-2, 
matrixmetalloproteinase-2; PINP, N-terminal pro-peptides of collagen I; PIIINP, N-terminal pro-peptides of collagen III; RQ, relative quantity.
associated with greater 6MWT distance from baseline, 
suggesting reversal of cardiac fibrosis was associated 
with improved functional status, in contrast to observa-
tions made by Garcia-Bolao et al.18 PIIINP was observed 
to be more sensitive to changes in cardiac modelling 
implying it may represent a more long-term remodel-
ling pattern. However, in the long term, these markers 
do not correlate with LV geometry parameters, there-
fore the precise relationship between collagen turn-
over and response to CRT remains unclear. We found 
that PINP, PIIINP and MMP-2 expression was higher 
in peripheral compared with coronary sinus samples. 
These observations are in agreement with findings 
of Tolsana et al,19 who reported MMP-2 was more 
highly expressed systemically than in the coronary 
sinus. Multiple cell types have been shown to secrete 
pro-MMP-2 that are not exclusive to the heart.3 The 
implications are that HF modifies systemic expression 
of MMP-2 alongside that of the heart. Furthermore, 
greater expression systematically suggests potential 
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Figure 5 Variation between biomarker expression in peripheral and coronary sinus blood. PIIINP is expressed as mean±SD 
and underwent parametric comparison. PINP, MMP-2, hs-TnT, miR-30d, miR-133a and miR-486 were reported as median 
(range) and underwent non-parametric comparison. Comparisons were undertaken on the number of paired datasets available 
(n given for each comparison). hs-TnT, high-sensitivity Troponin-T; MMP-2, matrixmetalloproteinase-2; PINP, N-terminal pro-
peptides of collagen I; PIIINP, N-terminal pro-peptides of collagen III.
modification of cardiac ECM in HF is from non-cardiac 
sources. GDF-15 is a marker of myocardial stress and its 
ability to predict poor HF outcomes are well described. 
GDF-15 has been demonstrated to be a robust predictor 
of mortality following CRT.5 However, GDF-15 did not 
predict functional response (survival/HF hospitalisa-
tions, ↓>1 NYHA class or ↑>25% 6 MWD at 1 year);5 our 
observations support these conclusions. GDF-15 did not 
predict response and we did not observe any difference 
in baseline expression in those with and without MACE.
There is maladaptation of complex cardiovascular 
biological systems in HF. This maladaptation involves 
dysregulation of specific miRNAs which regulate and 
control these systems.6 MiRNA dysregulation has 
been associated with development of adverse cardiac 
remodelling in HFrEF.6 Marfella et al7 observed altered 
expression in miRNA profiles between responders and 
non-responders using a miRNA microarray. Melman et 
al9 recently identified that miR-30d was overexpressed 
in responders and had ability to predict response 
(increase LVEF >10% at 6 months). Neither study 
replicated the results of the other; however, the studies 
differed in methodology. Marfella et al7 and Melman et 
al9 both used small cohorts with different characteristics 
and different quantification methods (microarray and 
quantitative PCR, respectively). We selected six specific 
miRNAs that have been demonstrated to be dysregu-
lated in HFrEF, including miR-30d. MiRNAs were indi-
vidually profiled by quantitative PCR methods, which is 
gold standard for quantification.6 None of the miRNAs 
were observed to be predictors of functional response 
and no variation at baseline was observed for echocar-
diographic responders. However, miR-30d had statisti-
cally higher expression in patients with no MACE at 12 
months. This observation has not previously been made 
and may imply increased LV wall stress is protective; 
however, this has not been tested in a prediction model 
against other variables. Over the observation period, 
miR-122 expression was statistically lower in functional 
responders. Recently, miR-122 has been shown to be 
expressed in the liver due to congestion which would 
support the observation that there is lower expres-
sion in responders after CRT.20 Higher expression of 
miR-30d and miR-133a was observed in the coronary 
sinus compared with peripheral circulation consistent 
with previous findings that demonstrated these miRNAs 
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to be enriched.6 MiR-486 demonstrated higher expres-
sion in the coronary sinus than peripherally, potentially 
reflecting higher haemolysis of samples taken via the 
catheter.
Our cohort behaved as expected following CRT 
implantation.1 18 19 Overall, patients had significantly 
improved NYHA classification and 6MWT distances, 
alongside reduced Qualiy of Life (QoL) scores. Interest-
ingly, the entire cohort showed a statistically significant 
improvement in LV geometry and reduction in hs-TnT 
over the observation period, without any difference 
between responders and non-responders. The pattern 
observed in overall improvement in LV geometry has 
been well described following CRT.1 However, given 
this pattern was not seen in functional responders only 
emphasises the known poor correlation between echo-
cardiographic and clinical response criteria.21 Variation 
in different definitions used for CRT response remains 
a major limitation in this field.21
There are several limitations to our prospective 
study. The first and most important is that our study 
was underpowered and may have affected the study 
findings. We were unable to perform power calcula-
tions at the start given the lack of data in the field. We 
performed this single-centre pilot study to allow us to 
subsequently perform a power calculation which would 
inform a larger multicentre trial. Therefore, a larger, 
powered sample size may demonstrate different results. 
Transthoracic echocardiography was limited in several 
participants due to body habitus resulting in inability 
to perform paired standardised modified Simpsons 
biplane assessments on all (28 paired assessments 
performed). The NICE implant guidelines10 used 
changed during the study period reflecting a move away 
from mechanical dys-synchrony on echo towards QRS 
duration/morphology. The study inclusion changed 
to reflect real world circumstances and this may have 
altered cohort characteristics. Also, the number of 
MACE events was low over 12 months and results must 
be interpreted cautiously. Coronary sinus samples were 
taken on the second half of the cohort only. Given the 
small sample size caution must be applied when inter-
preting these results. It is possible there may be a delay 
in ECM biomarkers/mRNA levels following CRT and 
longer follow-up may cause changes undetected during 
our follow-up.
ConClusIon
Our study showed that ECM biomarkers, GDF-15 and 
a selected panel of miRNAs did not predict functional 
response in a heterogeneous HFrEF population under-
going CRT. However, we observed LBBB morphology 
and the biomarker CTx did show a trend towards 
predicting response and warrants further study.
Author affiliations
1Department of Cardiology, University Hospital Coventry and Warwickshire NHS 
Trust, Coventry, UK
2Warwick Medical School, University of Warwick , Coventry, UK
3King's British Heart Foundation Centre, King's College London, London, UK
4Faculty of Education, Health and Wellbeing, University of Wolverhampton, 
Wolverhampton, UK
5Faculty of Health and Life Sciences, University of Coventry, Coventry, UK
Acknowledgements We acknowledge our manuscript appears in a plagiarism 
checker. We acknowledge textual overlap with Dr McAloon’s recent PhD thesis on 
this subject, which is held in a repository at the University of Warwick. We would 
like to thank the Research, Development and Innovation department at University 
Hospitals Coventry and Warwickshire for their support with the study as well as the 
Department of Cardiac Investigation. We would like to thank Dr Abdul Maher for 
implanting many of the devices included in the study.
Contributors All authors contributed to the planning, conduct and reporting of the 
work described in the article. FO is responsible for the overall content as guarantor.
Funding We would like to thank the Research, Development and Innovation 
department at University Hospitals Coventry and Warwickshire for their support with 
the study.
Competing interests None declared.
Patient consent Not required.
ethics approval South Birmingham Regional Ethics committee (13/WM/0355).
Provenance and peer review Not commissioned; externally peer reviewed.
data statement No additional data are available.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/
RefeRences
 1. Cleland JG, Daubert JC, Erdmann E. Cardiac resynchronization-
heart failure study I: the effect of cardiac resynchronization 
on morbidity and mortality in heart failure. N Engl J Med 
2005;352:1539–49.
 2. van Kimmenade RR, Januzzi JL. Emerging biomarkers in heart 
failure. Clin Chem 2012;58:127–38.
 3. Spinale FG, Janicki JS, Zile MR. Membrane-associated matrix 
proteolysis and heart failure. Circ Res 2013;112:195–208.
 4. McAloon CJ, Ali D, Hamborg T, et al. Extracellular cardiac matrix 
biomarkers in patients with reduced ejection fraction heart failure 
as predictors of response to cardiac resynchronisation therapy: a 
systematic review. Open Heart 2017;4:e000639.
 5. Foley PW, Stegemann B, Ng K, et al. Growth differentiation factor-15 
predicts mortality and morbidity after cardiac resynchronization 
therapy. Eur Heart J 2009;30:2749–57.
 6. Romaine SP, Tomaszewski M, Condorelli G, et al. MicroRNAs 
in cardiovascular disease: an introduction for clinicians. Heart 
2015;101:921–8.
 7. Marfella R, Di Filippo C, Potenza N, et al. Circulating microRNA 
changes in heart failure patients treated with cardiac 
resynchronization therapy: responders vs. non-responders. Eur J 
Heart Fail 2013;15:1277–88.
 8. Villar AV, García R, Merino D, et al. Myocardial and circulating levels 
of microRNA-21 reflect left ventricular fibrosis in aortic stenosis 
patients. Int J Cardiol 2013;167:2875–81.
 9. Melman YF, Shah R, Danielson K, et al. Circulating MicroRNA-30d 
Is associated with response to cardiac resynchronization therapy in 
heart failure and regulates cardiomyocyte apoptosis: a translational 
pilot study. Circulation 2015;131:2202–16.
 10. National Institute for Health and Clinical Excellence, 2014. 
Implantable cardioverter defibrillators and cardiac resynchronisation 
therapy for arrhythmias and heart failure (review of TA95 and TA120). 
Available from:  guidance. nice. org. uk/ ta314 [accessed 14 July 201].
 11. Atherton G, McAloon CJ, Chohan B, et al. Safety and cost-
effectiveness of same-day cardiac resynchronization therapy and 
implantable cardioverter defibrillator implantation. Am J Cardiol 
2016;117:1488–93.
 12. Lang RM, Bierig M, Devereux RB, et al. Recommendations for 
chamber quantification: a report from the American society of 
echocardiography's guidelines and standards committee and the 
chamber quantification writing group, developed in conjunction 
Open Heart
12 McAloon CJ, et al. Open Heart 2018;5:e000899. doi:10.1136/openhrt-2018-000899
with the European association of echocardiography, a branch 
of the european society of cardiology. J Am Soc Echocardiogr 
2005;18:1440–63.
 13. Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating 
microRNAs: a cautionary note for cancer biomarker studies. Cancer 
Prev Res 2012;5:492–7.
 14. Kaudewitz D, Skroblin P, Bender LH, et al. Association of MicroRNAs 
and YRNAs With platelet function. Circ Res 2016;118:420–32.
 15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. 
Methods 2001;25:402–8.
 16. Lopez-Andrès N, Rossignol P, Iraqi W, et al. Association of 
galectin-3 and fibrosis markers with long-term cardiovascular 
outcomes in patients with heart failure, left ventricular 
dysfunction, and dyssynchrony: insights from the CARE-HF 
(Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 
2012;14:74–81.
 17. Maass AH, Vernooy K, Wijers SC, et al. Refining success of cardiac 
resynchronization therapy using a simple score predicting the 
amount of reverse ventricular remodelling: results from the Markers 
and Response to CRT (MARC) study. Europace 2018;20:e1–e10.
 18. García-Bolao I, López B, Macías A, et al. Impact of collagen type 
I turnover on the long-term response to cardiac resynchronization 
therapy. Eur Heart J 2008;29:898–906.
 19. Tolosana JM, Mont L, Sitges M, et al. Plasma tissue inhibitor of 
matrix metalloproteinase-1 (TIMP-1): an independent predictor of 
poor response to cardiac resynchronization therapy. Eur J Heart Fail 
2010;12:492–8.
 20. Willeit P, Skroblin P, Kiechl S, et al. Liver microRNAs: potential 
mediators and biomarkers for metabolic and cardiovascular 
disease? Eur Heart J 2016;37:3260–6.
 21. Fornwalt BK, Sprague WW, BeDell P, et al. Agreement is poor among 
current criteria used to define response to cardiac resynchronization 
therapy. Circulation 2010;121:1985–91.
